Nevirapine is finally registered
The anti-retroviral drug, nevirapine, was finally registered yesterday (18 April) for use in preventing HIV transmission from mothers to their babies by the Medicines Control Council (MCC).
This opens the way for babies nationwide to get the drug, which manufacturer Boehringer Ingleheim has offered free to all SADC countries for a period of five years.
Drug trials completed nine months ago proved the safety and efficacy of the drug, which can cut the transmission rate of HIV from mothers to their babies by up to 50%.
However, the MCC was extremely cautious in its approach to registration of the drug, leading to speculation of government interference in the process.
The health department has, however, decided to offer HIV positive pregnant women free nevirapine at 18 pilot sites countrywide.
Cabinet has yet to approve the plan, which could save the lives of hundreds of babies. An estimated 1 800 HIV positive babies are born each day in this country.
MCC chairperson Professor Helen Rees confirmed yesterday that the drug had been registered after a “very satisfactory” agreement had been reached with its manufacturer, Boehringer Ingleheim.
Rees had earlier said that the MCC was concerned about the development of drug resistance, and this had been a stumbling block to the drug’s registration.
Kevin McKenna, Director of Technical Affairs for Boehringer Ingleheim, confirmed that his company had agreed to provide the MCC with “any information on adverse effects or non-effects” of the drug on an ongoing basis.
McKenna said a number of other countries including Uganda and Thailand had already approved nevirapine for prevention of mother-to-child HIV transmission.
The nevirapine programme has been in the pipeline since July last year, when it was approved by the health Minister and provincial MECs.
The Western Cape has already started giving Gugulethu women nevirapine, while KwaZulu-Natal, the Free State, Northern Cape and parts of Gauteng are ready to go ahead with their nevirapine programmes.
Author
Kerry Cullinan is the Managing Editor at Health-e News Service. Follow her on Twitter @kerrycullinan11
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Nevirapine is finally registered
by Kerry Cullinan, Health-e News
April 19, 2001